Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $292,645.38 in Stock

Key Points

• Supernus Pharmaceuticals CEO Jack Khattar sold 6,322 shares for $292,645.38, decreasing his ownership stake by 0.57%, now holding approximately 1.11 million shares valued at around $51.47 million.
• The stock of Supernus Pharmaceuticals has recently shown a market capitalization of $2.58 billion, with a price-to-earnings ratio of 40.03 and notable analyst upgrades, including a consensus rating of "Moderate Buy."
• Institutional investors are actively increasing holdings in Supernus Pharmaceuticals, with significant investments from firms such as Rubric Capital Management and Sofinnova Investments.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack A. Khattar sold 6,322 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $46.29, for a total value of $292,645.38. Following the completion of the sale, the chief executive officer directly owned 1,111,983 shares in the company, valued at approximately $51,473,693.07. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Supernus Pharmaceuticals Trading Down 2.6%

SUPN traded down $1.20 during trading on Friday, hitting $45.46. The company's stock had a trading volume of 415,075 shares, compared to its average volume of 624,694. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $46.78. The business's fifty day simple moving average is $39.42 and its 200 day simple moving average is $34.60. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of 39.53 and a beta of 0.79.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth approximately $25,000. Financial Management Professionals Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter worth approximately $30,000. Versant Capital Management Inc lifted its position in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Supernus Pharmaceuticals during the first quarter worth approximately $41,000. Finally, GF Fund Management CO. LTD. purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth approximately $42,000.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SUPN. Piper Sandler lifted their price target on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research note on Friday, August 29th. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Finally, Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.